Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

PODD - Insulet Corporation Последние новости | Finranks

Home

/

PODD

I

Insulet Corporation (PODD)

NMS – Цена в реальном времени. Валюта: USD

158.35

+4.18 (2.71%)

При закрытии: May 12, 2026, 4:00 PM EDT

158.40

+0.05 (0.03%)

До открытия: May 13, 2026, 8:46 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Here's Why Insulet (PODD) is a Strong Growth Stock

Here's Why Insulet (PODD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Insulet (PODD) is a Top Value Stock for the Long-Term

Why Insulet (PODD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript

Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript

Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript

Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Insulet (PODD) Q1 Earnings and Revenues Top Estimates

Insulet (PODD) Q1 Earnings and Revenues Top Estimates

Insulet (PODD) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.02 per share a year ago.

Insulin Pump-Maker Jumps On Beat And Raise

Insulin Pump-Maker Jumps On Beat And Raise

Insulet stock jumped early Wednesday on a solid first-quarter report and a sales guidance boost for the year.

Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand

Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand

Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless ‌insulin pumps that eliminate the need for daily injections.

Видео

Final Trades: Insulet Corp, Uber and Apollo Global

Пресс-релизы

Insulet Reports First Quarter 2026 Results

Insulet Reports First Quarter 2026 Results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4.

Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities

Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet's sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of.

Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes

Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.

Insulet to Participate in BofA Securities 2026 Health Care Conference

Insulet to Participate in BofA Securities 2026 Health Care Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet C.